Truncated 29-residue N-terminal fragment of native GHRH — retains full GH-releasing activity. Binds GHRH-R on somatotrophs → cAMP rise → GH release. Preserves physiologic negative-feedback loop (unlike direct HGH injection) so overtreatment risk is lower. Very short plasma t½ (~11 min) — divided or evening dosing.
Half-Life & Elimination Curve (SC: 4m)
Plasma (SC)t½ Decay (4m)
0×t½0h100%
1×t½4m50%
2×t½8m25%
3×t½13m12.5%
4×t½17m6.3%
5×t½21m3.1%
Elimination t½4m (SC)
Rate Constant (ke)9.9 h⁻¹
Time to Peak (Tmax)10m
Clearance (CL)69.3 L/h
97% Washout (5×t½)21m
Dosing Guidelines
Subcutaneous (SC): Typical 300 mcg (Range: 200–500 mcg)
Pharmacokinetic Parameters
Subcutaneous (SC): Volume of Distribution (Vd): 7 L · Absorption (ka): 3 h⁻¹ (t½ka ≈ 14m) [PMID 7962295]